CN102028705B - Gynecologic article containing biological antifungal components - Google Patents
Gynecologic article containing biological antifungal components Download PDFInfo
- Publication number
- CN102028705B CN102028705B CN201010527060.0A CN201010527060A CN102028705B CN 102028705 B CN102028705 B CN 102028705B CN 201010527060 A CN201010527060 A CN 201010527060A CN 102028705 B CN102028705 B CN 102028705B
- Authority
- CN
- China
- Prior art keywords
- epsilon
- gynecologic
- polylysine
- grams
- gynecological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000843 anti-fungal effect Effects 0.000 title abstract 3
- 229940121375 antifungal agent Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 20
- 235000010298 natamycin Nutrition 0.000 claims description 10
- 229920000656 polylysine Polymers 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 abstract description 32
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 208000016908 Female Genital disease Diseases 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000001408 fungistatic effect Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000004311 natamycin Substances 0.000 description 5
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 5
- 229960003255 natamycin Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- -1 thiamine alkyl sulfate Chemical class 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a gynecologic article containing biological antifungal components for preventing and treating gynecologic diseases clinically in the medicine field. The main active component is epsilon-polylysine, and the gynecologic article belongs to the fields of clinically used medicine and medical appliances. The gynecologic article used for preventing and treating the gynecologic diseases has good antifungal effect, high safety and no toxic side effect after entering the human body. The invention has the advantages of simple preparation process, low cost, high product stability, good clinical value and social significance of popularization and use.
Description
Technical field
The present invention relates to field of medicaments for a kind of gynecological's articles for use containing biological antipathogenic composition that prevent clinically and treat gynaecopathia, main active, for containing epsilon-polylysine, belongs to medicine and the medical apparatus and instruments category of clinical use.
Background technology
Gynaecopathia sickness rate was continuous rising situation in recent years, and vulvitis, vulval ulcer, vaginitis, uterine erosion etc. perplex the commonly encountered diseases frequently-occurring disease of modern female especially, and easily recurrence and cross infection.According to Ministry of Public Health investigation statistics, show, the women in life sickness rate of Symptomatic gynaecopathia is 75%, wherein approximately have half women to experience multiple relapse, after many women fall ill because of be subject to traditional view to affect mental pressure huge, have a strong impact on numerous women's health with physically and mentally healthy.At present a lot of patients adopt vagina administration mode to prevent and treat gynaecopathia, but life-time service contains sterilization, disinfection composition vagina preparation can be killed intravaginal normal flora, destroy intravaginal ecological environment, allow pathogenic bacteria take advantage of a weak point, thereby bring out all kinds of gynecological inflammations.
For this reason, the present invention proposes a kind of gynecological's articles for use containing biological antipathogenic composition, and its main active is epsilon-polylysine, can broad-spectrum antibacterial and without any side effect, can not cause the adverse consequencess such as intravaginal Flora Disturbance, drug resistance yet.
Epsilon-polylysine (ε-PL, molecular formula C
180h
362n
60) be that Japan screens and synthetic auxotype antibacterial at first.It is a kind of microbial metabolic products of biology, through separation and Extraction, refines and the fermented product of acquisition, connects the poly-l-lysine of carboxyl and amino group by peptide bond, is a kind of polypeptide with bacteriostasis efficacy.Because it has special molecular structure, thereby thering is special physics, chemistry and pharmacological properties, epsilon-polylysine has strong bacteriostasis, the membrane structure that it can destroy microorganisms, the material, energy and the information transmission that cause cell are interrupted, and finally cause cell death.Gram positive bacteria, gram negative bacteria, yeast, mycete are all had to good fungistatic effect, and very good to difficult escherichia coli, the Salmonella fungistatic effect suppressing of other antibacterial, thermostability bacillus cereus and some viruses are also had to inhibitory action.
Epsilon-polylysine is very good to the fungistatic effect of the pathogenic bacterium such as the common escherichia coli of intravaginal, staphylococcus aureus, in very low concentration, just can play inhibitory action.It is reported, when epsilon-polylysine concentration reaches 25mg/L, to staphylococcus aureus bacteriostasis clearly, and concentration is while reaching 50mg/L, plays bactericidal action; Colibacillary minimal inhibitory concentration is 5～10mg/L.But epsilon-polylysine is less to the inhibitory action of mycete.
Epsilon-polylysine has high safety, and Japan lists epsilon-polylysine in the bio-additive that allows interpolation in food in 1989, at US and European, has also listed food additive scope in.It is a kind of In Vitro Bacteriostasis agent of wide spectrum simultaneously, enter nutrition aminoacid---the lysine that can be decomposed into needed by human after human body, and one of lysine eight seed amino acids that to be human body necessary, therefore, epsilon-polylysine can not cause the adverse consequencess such as intravaginal Flora Disturbance, drug resistance after using.
Epsilon-polylysine good stability, has the features such as good water solubility, heat stability and the pH scope of application are wide, under various different conditions, all can use.Experiment shows, 80 ℃ of processing 60min of its aqueous solution, 100 ℃ of processing 30min, 120 ℃ of processing 20min character are all stablized, constant to colibacillary minimal inhibitory concentration, after heat treatment heat sterilization, microorganism is still had to bacteriostatic activity, and fungistatic effect is relatively stable in pH 5～8 scopes.
Other antibiotic property materials such as epsilon-polylysine and ethanol, glycine, thiamine alkyl sulfate have good cooperative effect, for example polylysine is 50ug/ml for colibacillary minimal inhibitory concentration, ethanol is 5% for colibacillary minimal inhibitory concentration, and both mix use and only need 0.025% ethanol of 5ug/ml polylysine just escherichia coli just to be had to strong inhibitory action.Epsilon-polylysine and other biological antiseptic, as compound uses such as glycine, malic acid, acetic acid, lactic acid natamycins, not only can make up the epsilon-polylysine deficiency poor to mycete fungistatic effect, and the corresponding consumption that reduces polylysine, thereby reduce the use cost of antibacterial.
Summary of the invention the present invention aims to provide a kind of for preventing clinically and a kind of gynecological's articles for use containing biological antipathogenic composition for the treatment of gynaecopathia, specific as follows:
1, the present invention relates to a kind of gynecological's articles for use containing biological antipathogenic composition, its main active is epsilon-polylysine.
2, the present invention relates to a kind of gynecological's articles for use containing biological antipathogenic composition, its dosage form refers to the regular dosage forms such as washing liquid, suppository, gel, capsule for vagina and tablet, also comprise that sorptive materials such as adopting absorbent cotton and nonwoven fabric makes band absorbent cotton bolt, cotton sliver, protective pad, sanitary towel, wet tissue, all can adopt the conventional adjuvant of above preparation and prior art to prepare.
3, a kind of gynecological's articles for use containing biological antipathogenic composition that the present invention relates to, the unit content of epsilon-polylysine in every gram or every ml of formulation is 1 μ g～200000 μ g, and the unit content that preferred version is epsilon-polylysine in every gram or every ml of formulation is 50 μ g～1000 μ g.
4, in the solution that epsilon-polylysine is 5～8 at pH value, fungistatic effect is best, and what therefore the present invention relates to is a kind of containing in gynecological's articles for use of biological antipathogenic composition, can also add pH value regulator.
5, epsilon-polylysine and ethanol, organic acid (acetic acid, lactic acid, malic acid, maleic acid etc.), glyceride, glycine have good synergism, what the present invention relates to is a kind of containing in gynecological's articles for use of biological antipathogenic composition, can also add above synergist; Addition and synergist kind according to the content of epsilon-polylysine than determining with dosage form situation.
6, epsilon-polylysine is poor to the fungistatic effect of mycete, so in prescription, the anti-mildew mushroom antipathogenic composition such as compatibility Nipagin ester, natamycin forms compound preparation and can expand antimicrobial spectrum, and clinical effectiveness is better.Natamycin has antibacterial activity to nearly all yeast and mycete, but invalid to antibacterial, protozoacide or sick element.Most of mycetes just can be suppressed when concentration 0.5～6ug/mL, but some mycete needs 10～25ug/mL.Most of yeast just can be suppressed in the concentration of 1.0～5.0ug/mL; Under 22mg/kg concentration, effect has killing action to Candida albicans, Aspergillus flavus.What the present invention relates to is a kind of containing in gynecological's articles for use of biological antipathogenic composition, can add the antibacterial such as biotinylated biomolecule antibacterial natamycin and make compound preparation.The proportion of composing of every gram or the every milliliter biological unit content of compound preparation is: 1 part～100 parts epsilon-polylysines, 1 part～10 parts natamycins, preferred version is 50 parts of epsilon-polylysines, 30 parts of natamycins.
7, a kind of gynecological's articles for use containing biological antipathogenic composition that the present invention relates to, its purposes is for pudendum cleaning, the prevention of vaginitis, cervicitis, cervical erosion, gynecopathy such as pelvic inflammatory disease and treatment.
8, a kind of gynecological's articles for use containing biological antipathogenic composition that the present invention relates to, can require to select and add the pharmaceutic adjuvant that appropriate difference requires according to dosage form.
The present invention is for prevention and the treatment of gynaecopathia, and not only good antimicrobial effect, simultaneously safe, has no side effect after entering human body.Preparation technology of the present invention is simple, with low cost, and product stability is high, the social meaning that has good clinical value and promote the use of.
Preparation method of the present invention is shown in the specific embodiment.
Specific embodiment the present invention can be illustrated with embodiment below
Embodiment 1 the technology of the present invention is prepared gynecological's articles for use.
Prescription:
Distilled water 10000ml
50 grams of epsilon-polylysines
Acetic acid is appropriate
Oleum menthae 5ml
Make 100 bottles
Preparation method:
1, in above prescription ratio precision, take 5 grams of epsilon-polylysine raw materials;
2, epsilon-polylysine is put in 10000ml distilled water, be stirred to completely and dissolve;
3, add Oleum menthae 5ml, be stirred to evenly;
4, slowly splash into acetic acid, make between pH value to 5.5～6.0;
5, according to every bottle of 100ml fill under purification condition, sealing;
6, detect after qualified and deposit.
Embodiment 2 the technology of the present invention are prepared gynecological suppository.
Prescription:
2000 grams of S-40
1 gram of epsilon-polylysine
0.6 gram of natamycin
Make 1000 pieces
Preparation method:
1, in above prescription ratio precision, take 1 gram of epsilon-polylysine raw material, 0.6 gram of natamycin.
2, get S-40 melts in water-bath;
3,, by epsilon-polylysine, natamycin raw material porphyrize, add the substrate of above-mentioned fusing to grind evenly;
4,, according to 2 grams every, mould is filled with in insulation, obtains suppository;
5, detect deposit after qualified standby.
Embodiment 3 the technology of the present invention are prepared gynecological's effervescent tablet.
Prescription:
5 grams of epsilon-polylysines
3 grams of natamycins
100 grams of lactose
220 grams of microcrystalline Cellulose
220 grams of citric acids
110 grams of sodium bicarbonate
Make 1000
Preparation method:
1, according to recipe quantity precision, take each supplementary material;
2, mix supplementary material, wear into fine powder, sieve;
3, tabletting and get final product.
Embodiment 3 the technology of the present invention are prepared medical device product---gynecological's absorbent-type tampon.
Prescription:
5 grams of epsilon-polylysines
Medicinal purified water 1000ml
1000 of defat tampons
Make 1000
Preparation method:
1, according to recipe quantity precision, take epsilon-polylysine;
2, epsilon-polylysine is dissolved in medicinal purified water, stirs;
3, according to every 1ml dosage by the solution absorbs configuring in defat tampon;
4, heat, dry defat tampon;
5, every of the defat tampon after drying is packed separately, obtained.
The invention is not restricted to above specific implementation method.
Claims (1)
1.Yi Zhong gynecological effervescent tablet, is characterized in that making 1000 by following composition: 5 grams of epsilon-polylysines, 3 grams of natamycins, 100 grams of lactose, 220 grams of microcrystalline Cellulose, 220 grams of citric acids, 110 grams of sodium bicarbonate; Preparation method is:
(1) according to recipe quantity precision, take each supplementary material;
(2) mix supplementary material, wear into fine powder, sieve;
(3) tabletting and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010527060.0A CN102028705B (en) | 2010-11-01 | 2010-11-01 | Gynecologic article containing biological antifungal components |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010527060.0A CN102028705B (en) | 2010-11-01 | 2010-11-01 | Gynecologic article containing biological antifungal components |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102028705A CN102028705A (en) | 2011-04-27 |
| CN102028705B true CN102028705B (en) | 2014-05-07 |
Family
ID=43882515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010527060.0A Active CN102028705B (en) | 2010-11-01 | 2010-11-01 | Gynecologic article containing biological antifungal components |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102028705B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389743A (en) * | 2011-06-14 | 2012-03-28 | 陈旭良 | Formula of medical bacteriostatic humidifying solution |
| CN102326546A (en) * | 2011-07-07 | 2012-01-25 | 郑州拜纳佛生物工程股份有限公司 | Leave-on bio-bacteriostat |
| CN102941034A (en) * | 2011-11-18 | 2013-02-27 | 曹青春 | Medical humidification liquid having bacteriostasis function |
| CN103316330B (en) * | 2012-06-28 | 2016-03-09 | 西藏贝珠雅药业有限公司 | A kind of prescription of soft-tissue trauma nursing material and purposes |
| CN106726710B (en) * | 2016-12-22 | 2019-10-18 | 北京刷新活力健康科技有限公司 | A kind of effervescent tablet and the preparation method and application thereof containing polylysine and parahydroxyacet-ophenone |
| CN106943425A (en) * | 2017-03-01 | 2017-07-14 | 北京德得创业科技有限公司 | A kind of gynaecology sterilization gel of wound healing and preparation method and application |
| CN107823696A (en) * | 2017-09-22 | 2018-03-23 | 北京大清生物技术股份有限公司 | A kind of water suction biocidal property material for personal-care supplies and preparation method thereof |
| CN108186404A (en) * | 2018-01-17 | 2018-06-22 | 南阳师范学院 | A kind of vulva washing lotion containing polylysine and preparation method thereof |
| CN111202069A (en) * | 2020-02-13 | 2020-05-29 | 军事科学院系统工程研究院卫勤保障技术研究所 | Disinfectant, and preparation method and application thereof |
| CN114767708B (en) * | 2022-05-23 | 2024-01-23 | 珠海凤凰高科生物制药有限公司 | Stable gynecological antibacterial composition and gynecological care solution |
| CN115192696B (en) * | 2022-07-13 | 2023-07-14 | 翔宇药业股份有限公司 | Active antibacterial gynecological lotion and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009037269A1 (en) * | 2007-09-17 | 2009-03-26 | Purac Biochem Bv | New antibacterial agent based on fatty acid esters of hydroxy carboxylic acids |
| CN101822736A (en) * | 2010-03-08 | 2010-09-08 | 深圳市倍安蒂科技有限公司 | Novel biological bactericide and preparation method thereof |
-
2010
- 2010-11-01 CN CN201010527060.0A patent/CN102028705B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102028705A (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028705B (en) | Gynecologic article containing biological antifungal components | |
| CN103285028B (en) | Composite antibacterial agent of chitosan and organosilicone quaternary ammonium salt and preparation method of composite antibacterial agent | |
| EP3520785B1 (en) | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use | |
| CN101791319B (en) | Female pudendum nursing product | |
| EP2775838B1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
| CN101953860B (en) | Wet tissue for relieving hemorrhoid symptom and production method thereof | |
| CN106309401A (en) | Bathing effervescent tablets for preventing and treating skin diseases | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN104173871B (en) | A kind of Chinese medicine composition for treating vulvitis and its application | |
| CN106074291A (en) | A kind of Artemisia argyi Levl. et Van. var. argyi cv. Qiai bacteriostatic lotion | |
| CN113995744B (en) | Composition and antibacterial application thereof | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| CN102824337B (en) | Compound chlorhexidine acetate gel for treating livestock endometritis, and preparation method thereof | |
| CN104667267A (en) | Lysozyme compound agent for skin external use and preparation method of lysozyme compound agent | |
| CN102614294B (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN101744926B (en) | Chinese medicinal antibacterial lotion and preparation method thereof | |
| KR102061302B1 (en) | Feminine cleanser having antimicrobial and deodorizing function | |
| CN1969838A (en) | Micro-ecological preparation for treating moniliasis | |
| CN105055439B (en) | A kind of microecology in vaginas maintenance, health care and prevention preparation and preparation method and application | |
| KR20210130870A (en) | Feminine cleanser containing salt and quercus infectoria oak gall extract | |
| CN105055713A (en) | Drug composition for preventing or curing bedsore and preparation method thereof | |
| KR20210082009A (en) | Composition comprising cis-jasmone for inhibiting the formation of biofilm | |
| CN111632073A (en) | Antibacterial and anti-inflammatory female privates probiotic composition and preparation thereof | |
| CN102552888B (en) | Suppository for treating mammal endometritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240226 Address after: 850000 Yajiang Industrial Park, Qushui County, Lhasa, Xizang Autonomous Region Patentee after: Tibet Bezhuya Pharmaceutical (Group) Co.,Ltd. Country or region after: China Address before: No. 39, Lhasa South Road, Naqu Town, Naqu Prefecture, Xizang Autonomous Region 852000 Patentee before: TIBET BEIZHUYA PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |